Gilead reports Q2 GAAP net income down at US$1.1B from US$1.5B a year ago, revenue up at US$6.3B from US$6.2B a year ago; excluding Veklury, product sales grew 7% year-over-year, with high demand for HIV portfolio, oncology revenues reaching all-time high

FOSTER CITY, California , August 4, 2022 (press release) –

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2022.

“This was a very strong quarter for Gilead, with solid commercial and clinical execution,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “Excluding Veklury, product sales grew 7% year-overyear. There was continued strong demand for our HIV portfolio with further share growth for Biktarvy, and oncology revenues reached an all-time high, driven by cell therapy and Trodelvy.”

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.